Invitrogen™
life technologies

Gateway® LR Clonase™ II Enzyme Mix

Cat. No. 11791-020 **Size: 20 reactions**
Cat. No. 11791-100 **Size: 100 reactions**
Store at -20°C (non-frost-free freezer)

Gateway® Technology

The Gateway® Technology is a universal cloning method that takes advantage of the site-specific recombination properties of bacteriophage lambda (1) to provide a rapid and highly efficient way to move DNA sequences into multiple vector systems. The Gateway® Technology is schematically represented below.



The *att*B × *att*P reaction is mediated by Gateway® BP Clonase™ II enzyme mix; the *att*L × *att*R reaction is mediated by Gateway® LR Clonase™ II enzyme mix. *ccd*B is the F plasmid-encoded gene that inhibits growth of *E. coli* (2,3) and "gene" represents any DNA segment of interest (*e.g.* PCR product, cDNA, genomic DNA).

Description

Gateway® LR Clonase™ II enzyme mix is a proprietary enzyme and buffer formulation containing the bacteriophage lambda recombination proteins Integrase (Int) and Excisionase (Xis), the *E. coli*-encoded protein Integration Host Factor (IHF) (1), and reaction buffer provided in a single mix for convenient reaction set up. Gateway® LR Clonase™ II enzyme mix catalyzes *in vitro* recombination between an entry clone (*att*L-flanked "gene") and an *att*R-containing destination vector to generate an *att*B-containing expression clone. Store Gateway® LR Clonase™ II enzyme mix at -20ºC (non-frost-free freezer) for up to 6 months. For long-term storage, store at -80ºC.

Components Supplied	20 rxns	100 rxns
Gateway® LR Clonase™ II Enzyme Mix	40 µl	200 µl
Proteinase K Solution (2 µg/µl)	40 µl	200 µl
pENTR™-gus Positive Control (50 ng/µl)	20 µl	20 µl

Quality Control

LR Clonase™ II enzyme mix is functionally tested in a 1 hour recombination reaction followed by a transformation assay.

Part No. 11791.II.pps Rev. Date: 10 Jun 2004

This product is distributed for laboratory research only. CAUTION: Not for diagnostic use. The safety and efficacy of this product in diagnostic or other clinical uses has not been established.

General Recommendations and Guidelines

- pENTR™-gus is provided for use as a positive control in the LR reaction and is an entry clone containing the *Arabidopsis thaliana* β-glucuronidase (*gus*) gene (4). Refer to our Web site (www.invitrogen.com) for a map and sequence of pENTR™-gus.

- We recommend using plasmid DNA purified with the PureLink™ HQ Mini Plasmid Purification Kit (Catalog no. K2100-01). Mini-prep (alkaline lysis) DNA preparations are adequate for Gateway® cloning reactions; however, in general, such DNA cannot be quantitated by UV absorbance due to contaminating RNA and nucleotides. Estimate concentrations by gel electrophoresis in comparison with standard DNA (*e.g.* DNA Mass Ladder, Catalog no. 10068-013 or 10496-016).

- For LR recombination reactions, the most efficient substrates are supercoiled *att*L-containing entry vectors and supercoiled *att*R-containing destination vectors. For large (>10 kb) entry clones or destination vectors, linearizing the entry clone or destination vector may increase the efficiency by up to 2-fold.

- To increase the number of colonies containing the desired expression clone, increase the incubation time from the recommended 1 hour to 2 hours-overnight. Longer incubations are recommended for plasmids ≥10 kb to increase the yield of colonies.

- We recommend using 50-150 ng entry clone per 10 µl reaction. Highest colony yields are typically obtained using 150 ng entry clone and 150 ng destination vector. Do not use >150 ng entry clone as you may obtain colonies containing multiple DNA molecules (often with an associated "small colony" phenotype). Using <50 ng entry clone will generate fewer colonies.

Procedures

LR Reaction

LR Clonase™ II enzyme mix is supplied as a 5X solution. If you wish to scale the reaction volume, make sure the LR Clonase™ II enzyme mix is at a final concentration of 1X. For a positive control, use 100 ng (2 µl) of pENTR™-gus.

1. Add the following components to a 1.5 ml microcentrifuge tube at room temperature and mix:

Entry clone (50-150 ng)	1-7 µl
Destination vector (150 ng/µl)	1 µl
TE buffer, pH 8.0	to 8 µl

2. Thaw on ice the LR Clonase™ II enzyme mix for about 2 minutes. Vortex the LR Clonase™ II enzyme mix briefly twice (2 seconds each time).
3. To each sample (Step 1, above), add 2 µl of LR Clonase™ II enzyme mix to the reaction and mix well by vortexing briefly twice. Microcentrifuge briefly.
4. Return LR Clonase™ II enzyme mix to -20°C or -80°C storage.
5. Incubate reactions at 25°C for 1 hour.
6. Add 1 µl of the Proteinase K solution to each sample to terminate the reaction. Vortex briefly. Incubate samples at 37°C for 10 minutes.

Transformation

1. Transform 1 µl of each LR reaction into 50 µl of One Shot® OmniMAX™ 2 T1 Phage-Resistant Cells (Catalog no. C8540-03). Incubate on ice for 30 minutes. Heat-shock cells by incubating at 42°C for 30 seconds. Add 250 µl of S.O.C. Medium and incubate at 37°C for 1 hour with shaking. Plate 20 µl and 100 µl of each transformation onto selective plates. **Note:** Any competent cells with a transformation efficiency of >1.0×10^8 transformants/µg may be used.
2. Transform 1 µl of pUC19 DNA (10 ng/ml) into 50 µl of One Shot® OmniMAX™ 2 T1 Phage-Resistant Cells as described above. Plate 20 µl and 100 µl on LB plates containing 100 µg/ml ampicillin.

Expected Results

An efficient LR recombination reaction will produce >5000 colonies if the entire LR reaction is transformed and plated.

References

1. Landy, A. (1989) *Ann. Rev. Biochem*. *58*, 913.
2. Bernard, P. and Couturier, M. (1992) *J. Mol. Biol. 226*, 735.
3. Miki, T., Park, J.A., Nagao, K., Murayama, N., and Horiuchi, T. (1992) *J. Mol. Biol. 225,* 39.
4. Kertbundit, S., Greve, H.D., Deboeck, F., Montagu, M.V., and Hernalsteens, J.P. (1991) *Proc. Natl. Acad. Sci. USA*, *88*, 5212.

Limited Use Label License No. 19: Gateway® Cloning Products

This product and its use is the subject of one or more of U.S. Patent Nos. 5,888,732, 6,143,557, 6,171,861, 6,270,969, 6,277,608, and 6,720,140 and/or other pending U.S. and foreign patent applications owned by Invitrogen Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for profit entity). The purchase of this product does not convey a license under any method claims in the foregoing patents or patent applications, or to use this product with any recombination sites other than those purchased from Invitrogen Corporation or its authorized distributor. The right to use methods claimed in the foregoing patents or patent applications with this product for research purposes only can only be acquired by the use of Clonase™ purchased from Invitrogen Corporation or its authorized distributors. The buyer cannot modify the recombination sequence(s) contained in this product for any purpose. The buyer cannot sell or otherwise transfer (a) this product, (b) its components, or (c) materials made by the employment of this product or its components to a third party or otherwise use this product or its components or materials made by the employment of this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the employment of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Notwithstanding the preceding, any buyer who is employed in an academic or government institution may transfer materials made with this product to a third party who has a license from Invitrogen under the patents identified above to distribute such materials. Transfer of such materials and/or information to collaborators does not convey rights to practice any methods claimed in the foregoing patents or patent applications. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Invitrogen Corporation will not assert a claim against the buyer of infringement of the above patents based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that none of (i) this product, (ii) any of its components, or (iii) a method claim of the foregoing patents, was used in the manufacture of such product. Invitrogen Corporation will not assert a claim against the buyer of infringement of the above patents based upon the use of this product to manufacture a protein for sale, provided that no method claim in the above patents was used in the manufacture of such protein. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to use this product for purposes other than those permitted above, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200.

Limited Use Label License No. 23: GUS Control Vector

The GUS positive control vector in these products is claimed in patents and patent applications (See U.S. Patent No. 5,599,670 and Great Britain Patent No. 2,197,653) licensed to Invitrogen by Cambia Biosystems, L.L.C. ("CBL"). Use of the GUS gene is restricted to use as a positive control. Any other use may require a license from CBL.

©2004 Invitrogen Corporation. All rights reserved.